2. Epigenetics PI3K/Akt/mTOR Cell Cycle/DNA Damage Autophagy Apoptosis
  3. Epigenetic Reader Domain Akt CDK Autophagy Apoptosis
  4. BRD4/AKT-IN-1

BRD4/AKT-IN-1 is a BRD4/AKT inhibitor with BRD4 IC50 66.12 nM and AKT1 IC50 143.81 nM. BRD4/AKT-IN-1 blocks BRD4-mediated c-Myc transcriptional regulation, modulates AKT1 signaling, decouples AKT phosphorylation from pro-survival effectors. BRD4/AKT-IN-1 induces G0/G1 cell cycle arrest via downregulated phosphorylated RB, cyclin E1, CDK2. BRD4/AKT-IN-1 elevates LC3B levels to promote autophagy. BRD4/AKT-IN-1 promotes apoptosis in cancer cells. BRD4/AKT-IN-1 can be used for the research of metastatic castration-resistant prostate cancer.

For research use only. We do not sell to patients.

BRD4/AKT-IN-1

BRD4/AKT-IN-1 Chemical Structure

CAS No. : 3087270-50-3

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

BRD4/AKT-IN-1 Related Antibodies

Top Publications Citing Use of Products

View All Akt Isoform Specific Products:

View All Isoforms
Akt Akt1 Akt2 Akt3

View All CDK Isoform Specific Products:

View All Isoforms
CDK1 CDK2 CDK3 CDK4 CDK5 CDK6 CDK7 CDK8 CDK9 CDK11 CDK12 CDK13 CDK14 CDK16 CDK19 CDC CLK Pho85 CDK10 CDK15 CDK17 CDK18 CDK20 PITSLRE

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

BRD4/AKT-IN-1 is a BRD4/AKT inhibitor with BRD4 IC50 66.12 nM and AKT1 IC50 143.81 nM. BRD4/AKT-IN-1 blocks BRD4-mediated c-Myc transcriptional regulation, modulates AKT1 signaling, decouples AKT phosphorylation from pro-survival effectors. BRD4/AKT-IN-1 induces G0/G1 cell cycle arrest via downregulated phosphorylated RB, cyclin E1, CDK2. BRD4/AKT-IN-1 elevates LC3B levels to promote autophagy. BRD4/AKT-IN-1 promotes apoptosis in cancer cells. BRD4/AKT-IN-1 can be used for the research of metastatic castration-resistant prostate cancer[1].

IC50 & Target[1]

BRD4

66.12 nM (IC50)

Akt1

143.81 nM (IC50)

CDK2/cyclin E1

 

In Vitro

BRD4/AKT-IN-1 (Compound 21d) (300-1000 nM) potently inhibits purified BRD4 (IC50 = 66.12 nM) and AKT1 (IC50 = 143.81 nM) proteins in a cell-free biochemical HTRF assay[1].
BRD4/AKT-IN-1 (0.01-100 μM; 72 h) potently inhibits the proliferation of 22Rv1 (IC50 = 0.51 μM), VCaP (IC50 = 0.69 μM), and PC3 (IC50 = 4.62 μM) mCRPC cells in a MTT antiproliferation assay[1].
BRD4/AKT-IN-1 (0.5-2 μM; 24 h) induces dose-dependent G0/G1 phase cell cycle arrest in 22Rv1 mCRPC cells by downregulating the expression of p-RB, cyclin E1, and CDK2[1].
BRD4/AKT-IN-1 (0.5-2 μM; 48 h) dose-dependently inhibits the migration of 22Rv1 mCRPC cells in a wound healing assay[1].
BRD4/AKT-IN-1 (0.5-2 μM; 12-14 days) dose-dependently suppresses the long-term clonogenic proliferative capacity of 22Rv1 mCRPC cells[1].
BRD4/AKT-IN-1 (0.5-2 μM; 24 h) dose-dependently suppresses the BRD4/c-Myc pathway and modulates AKT phosphorylation without activating downstream pro-survival signaling in 22Rv1 mCRPC cells after 24 h of treatment[1].
BRD4/AKT-IN-1 (0.5-2 μM; 24 h) dose-dependently induces autophagy in 22Rv1 mCRPC cells after 24 h of treatment, as shown by increased MDC-positive vesicles and elevated LC3B protein levels[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

BRD4/AKT-IN-1 Related Antibodies

Cell Cycle Analysis[1]

Cell Line: 22Rv1 mCRPC cells
Concentration: 0.5 μM; 1 μM; 2 μM
Incubation Time: 24 h
Result: Induced a dose-dependent accumulation of cells in the G0/G1 phase, with 51.9% of untreated cells in G0/G1 increasing to higher proportions with compound treatment.
Downregulated phosphorylated RB (p-RB), cyclin E1, and CDK2 protein levels in a dose-dependent manner.

Cell Migration Assay [1]

Cell Line: 22Rv1 mCRPC cells
Concentration: 0.5 μM; 1 μM; 2 μM
Incubation Time: 48 h
Result: Demonstrated dose-dependent inhibition of wound closure, with higher concentrations resulting in significantly less migration compared to the control.

Cell Proliferation Assay[1]

Cell Line: 22Rv1 mCRPC cells
Concentration: 0.5 μM; 1 μM; 2 μM
Incubation Time: 12-14 days
Result: Significantly reduced colony formation in a dose-dependent manner, with fewer and smaller colonies observed at higher compound concentrations.

Western Blot Analysis[1]

Cell Line: 22Rv1 mCRPC cells
Concentration: 0.5 μM; 1 μM; 2 μM
Incubation Time: 24 h
Result: Reduced the expression of c-Myc (a BRD4 transcriptional target) in a dose-dependent manner, with efficacy comparable to positive control BRD4 inhibitors.
Induced a dose-dependent increase in p-AKT (Ser473) but did not activate downstream effectors p-PRAS40 and p-S6.

Cell Autophagy Assay[1]

Cell Line: 22Rv1 mCRPC cells
Concentration: 0.5 μM; 1 μM; 2 μM
Incubation Time: 24 h
Result: Increased the number of MDC-positive autophagic vesicles in a dose-dependent manner.
Induced a dose-dependent upregulation of LC3B protein levels, confirming autophagy induction.
Parmacokinetics
Species Dose Route T1/2 Tmax Cmax
Mice[1] 40 mg/kg i.p. 6.8 h 0.25 h 16967 ng/mL
In Vivo

BRD4/AKT-IN-1 (Compound 21d) (40-80 mg/kg; i.p.; daily; 18 days) exhibits dose-dependent antitumor efficacy in a 22Rv1 prostate cancer xenograft model, achieving a 62.0% tumor growth inhibition rate at the 80 mg/kg daily intraperitoneal dose with favorable tolerability[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c nude (male; subcutaneously injected 22Rv1 cells into the right flank to form a xenograft model)[1]
Dosage: 40 mg/kg; 80 mg/kg
Administration: i.p.; daily; 18 days
Result: Achieved a tumor growth inhibition (TGI) rate of 37.7% with no observable body weight loss or treatment-related mortality.
Achieved a TGI rate of 62.0%, which was superior to capivasertib monotherapy, compound 15 monotherapy, and their combination.
Significantly reduced tumor volume and tumor weight compared to controls, with no significant body weight loss or histopathological lesions in major organs (heart, liver, spleen, lung, kidney).
Molecular Weight

926.55

Formula

C51H60ClN11O4
CAS No.
SMILES

CC1=NOC(C)=C1C2=CC=C3C(C(N(C(N3C)=O)CCCCCC(N4CCN(CC4)CC[C@@H](C5=CC=C(C=C5)Cl)NC(C6(CCN(CC6)C7=C8C=CNC8=NC=N7)N)=O)=O)C9=CC=CC=C9)=C2
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

BRD4/AKT-IN-1 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

BRD4/AKT-IN-13087270-50-3Epigenetic Reader DomainAktCDKAutophagyApoptosisPKBProtein kinase BCyclin dependent kinaseG0/G1 cell cycle arrestc-Mycxenograft mouse modelautophagymetastatic castration-resistant prostate cancerAKT1apoptosisBRD422Rv1LC3BInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
BRD4/AKT-IN-1
Cat. No.:
HY-183273
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.